|
|
Volumn 508, Issue 1, 2014, Pages 16-17
|
|
Regulators adopt more orphan drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IVACAFTOR;
ORPHAN DRUG;
CANCER;
DISEASE TREATMENT;
DRUG DEVELOPMENT;
EUROPEAN UNION;
IMMUNITY;
INVESTMENT;
MEDICINE;
REGULATORY APPROACH;
SCIENCE AND TECHNOLOGY;
ARTICLE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
INCOME;
INVESTMENT;
LYMPHOMA;
PRIORITY JOURNAL;
RARE DISEASE;
SICKLE CELL ANEMIA;
ENGLAND;
LONDON [ENGLAND];
UNITED KINGDOM;
ANEMIA, SICKLE CELL;
CYSTIC FIBROSIS;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
ORPHAN DRUG PRODUCTION;
RARE DISEASES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84897565811
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/508016a Document Type: Article |
|
Times cited : (15)
|
|
References (0)
|
